AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
PROCEPT BioRobotics Sets $325.5M 2025 Revenue Target Amid Leadership Change and Margin Expansion
ByAinvest
Thursday, Aug 7, 2025 2:21 am ET1min read
PROCEPT BioRobotics Corporation has outlined a $325.5M revenue target for 2025 amid a leadership transition and plans for margin expansion. CEO Reza Zadno emphasized the company's strength, citing sustainable growth drivers. The company expects to exit 2025 with a strong position, supported by its leadership transition and growth drivers.
SAN JOSE, Calif., Aug. 06, 2025 (GLOBE NEWSWIRE) — PROCEPT BioRobotics Corporation (Nasdaq: PRCT) reported its second-quarter 2025 financial results, showing a 48% year-over-year increase in total revenue to $79.2 million. The company also raised its full-year 2025 revenue guidance to $325.5 million, a 45% increase over the prior year. This growth is driven by robust global demand and sustained procedural momentum, according to CEO Reza Zadno.Key highlights of the second quarter include:
- Total revenue of $79.2 million, up 48% year-over-year.
- U.S. handpiece and consumables revenue of $43.1 million, up 58% year-over-year.
- U.S. system and rental revenue of $22.1 million, up 24% year-over-year.
- International revenue of $9.6 million, up 69% year-over-year.
- Gross margin expanded to 65% from 59% in the prior year.
The company's leadership transition is also notable. Larry Wood, with 40 years of experience in the global medical technology industry, has been appointed as the new CEO, effective September 2, 2025.
PROCEPT BioRobotics expects to maintain its momentum into the second half of 2025, supported by its Aquablation® therapy expansion in the U.S. and continued growth in key international markets. The company projects a full-year 2025 gross margin of approximately 64.5%, with a potential gross margin headwind of $1.0 to $2.0 million due to current global tariff rates.
The company's financial results were presented in a conference call on Wednesday, August 6, 2025, at 4:30 p.m. Eastern Time. Investors can access the webcast and dial-in registration for sell-side research analysts via the links provided in the press release.
References:
[1] https://finance.yahoo.com/news/procept-biorobotics-reports-second-quarter-200300221.html
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet